Tabimorelin

CAS: 193079-69-5

Ref. TR-T003500

Información del producto

• Nombre: Tabimorelin
• Sinónimos: (R)-alpha-((E)-5-Amino-N,5-dimethyl-2-hexenamido)-N-methyl-N-((R)-alpha-(methylcarbamoyl)phenethyl)-2-naphthalenepropionamide, <span class="text-smallcaps">D</smallcap>-Phenylalaninamide, N-[(2E)-5-amino-5-methyl-1-oxo-2-hexen-1-yl]-N-methyl-3-(2-naphthalenyl)-<smallcap>D</span>-alanyl-N,N^α-dimethyl-, <span class="text-smallcaps">D</smallcap>-Phenylalaninamide, N-[(2E)-5-amino-5-methyl-1-oxo-2-hexenyl]-N-methyl-3-(2-naphthalenyl)-<smallcap>D</span>-alanyl-N,N^α-dimethyl-, N-[(2E)-5-Amino-5-methyl-1-oxo-2-hexen-1-yl]-N-methyl-3-(2-naphthalenyl)-<span class="text-smallcaps">D</smallcap>-alanyl-N,N^α-dimethyl-<smallcap>D</span>-phenylalaninamide, N-[(2E)-5-amino-5-methylhex-2-enoyl]-N-methyl-3-(naphthalen-2-yl)-D-alanyl-N,Nα-dimethyl-D-phenylalaninamide, Nn 703, Nnc 26-0703, Tabimorelin [INN], Unii-L51Cbe03Kf
• CAS: 193079-69-5

Descripción

Applications NN703 (Tabimorelin) is an orally active growth hormone (GH) secretagogue intended for use as an alternative to daily injections of GH. In vitro studies in human liver microsomes have indicated that NN703 is a mechanism-based inhibitor of CYP3A4.
References Fabre, G., et al.: Biochem. Pharmacol., 37, 4389 (1988), Thummel, K., et al.: Clin. Pharmacol. Ther., 59, 491 (1996), Yu, D., et al.: J. Clin. Pharmacol., 39, 1203 (1999),

• Marca: TRC

Propiedades químicas

• Peso molecular: 528.68
• Fórmula: C₃₂H₄₀N₄O₃
• Color/Forma: White to Off-White Solid
• InChI: InChI=1S/C32H40N4O3/c1-32(2,33)19-11-16-29(37)35(4)28(22-24-17-18-25-14-9-10-15-26(25)20-24)31(39)36(5)27(30(38)34-3)21-23-12-7-6-8-13-23/h6-18,20,27-28H,19,21-22,33H2,1-5H3,(H,34,38)/b16-11+/t27-,28-/m1/s1
• Clave InChI: InChIKey=WURGZWOTGMLDJP-GBDBBNHTSA-N
• SMILES: CNC(=O)[C@@H](Cc1ccccc1)N(C)C(=O)C(Cc1ccc2ccccc2c1)N(C)C(=O)/C=C/CC(C)(C)N